TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05830500: A Real World Study of Anlotinib for Patients With Advanced Medullary Thyroid Carcinoma

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,728,800

Rescue Site Savings

+$3,769,920

Unlock Full NCT05830500 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05830500 Rescue Dossier →